"The primary end point was radiographic progression-free survival, which we reported in 2023, and we updated the radiographic progression-free survival data in 2025," says Neeraj Agarwal, MD, FASCO.

Experts review different treatment delivery options available for the management of non–muscle-invasive bladder cancer (NMIBC), discuss the exciting developments in NMIBC with several delivery systems ...

Panelists discuss how the combination of radium-223 and enzalutamide (RAD-ENZ) demonstrated a manageable safety profile in PEACE-3, with bone health monitoring and prophylactic bone-targeted therapy ...

Experts discuss the frequency of cystectomy use in patients with non–muscle-invasive bladder cancer (NMIBC) and how often patients are requesting bladder-sparing treatments.

Panelists discuss how the PEACE-3 trial demonstrated meaningful clinical benefits with the combination of radium-223 and enzalutamide compared with enzalutamide alone in patients with metastatic ...

"It was a really interesting paper to develop and write, because over the past decade, there's been such a paradigm shift in the treatment of prostate cancer," says Dr Louise Kostos. In this video, Dr ...

"At 3 months, those patients had a 79% complete response rate, which was durable in 74% at 6 months and 60% at 9 months," says Jacob A. Moyer, BS. Moyer: Since nadofaragene firadenovec was approved in ...

The updated guideline includes 25 recommendations, emphasizing risk stratification and minimizing unnecessary evaluations for low-risk patients. New guidance incorporates urine-based tumor markers for ...

64Cu-SAR-bisPSMA detected prostate cancer lesions in up to 80% of patients with biochemical recurrence, outperforming standard imaging methods. Histopathology confirmed prostate cancer in 78% of ...

In this video, Gopa Iyer, MD, shares the background and preliminary findings from the phase 1/2 SURF301 (NCT05544552) trial of TYRA-300 in advanced/metastatic urothelial carcinoma.Iyer is a ...

Experts discuss the standard of care and the use of intravesical chemotherapy in the treatment of non–muscle-invasive bladder cancer (NMIBC).

"[Urologists] really need to understand how big the prostate is and how big of a surgery that they're looking at," says Amy E. Krambeck, MD. In this video, Amy E. Krambeck, MD, shares her perspective ...